Browse drugs

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

… B, Feinstein T, Shi Y, et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progr…

…k sac of zebrafish embryos, followed by systemic treatment with Docetaxel. Tumor burden was quantified using fluorescence microscopy, and…

…AR1302 (1mg/kg) was administered once per week for 3 weeks, and docetaxel (500µg) in 3 doses, every other day, for 1 week. Tumors, spleen…

…ypically delivered 5 days a week over 7 weeks concurrently with cisplatin, a regimen established through multiple randomised trials, demo…

…xel arm. Grade 5 haemoptysis occurred in 3 (1.6%) patients with sitravatinib plus tislelizumab. The study was terminated due to an unfavoura…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…linded), vibo/pembro alone (arm 2; open label), or placebo plus docetaxel (arm 3; blinded). PD-L1 expression was assessed using PD-L1 IHC…

…hibitor sensitized the tumor cells to the cytotoxic activity of docetaxel. In addition, in vivo, treatment of HNSCC xenograft models with…

…arm, 7.5% in the atezolizumab+bevacizumab arm, and 15.4% in the docetaxel (control) arm. There were no clear correlations of response or …

…nalysis of the phase 3 PHILA trial confirmed the superiority of pyrotinib in combination with trastuzumab and docetaxel over placebo in c…

…k M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Englan…